The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment

被引：0
|
作者：
Jin, Shanshan
Zhang, Xiaochen
Jia, Yunlu
Dai, Yongchao
Xu, Fengwei
Huang, Yongfeng
Wang, Xun
Wu, Hailong
Shao, Yu
Long, Jinfeng
Zheng, Anjie
Xu, Yuhong
机构：
[1] Hangzhou HighField Biopharmaceut Corp, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Pharm, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
    LoRusso, Patricia
    Venkatakrishnan, Karthik
    Chiorean, E. Gabriela
    Noe, Dennis
    Wu, Jing-Tao
    Sankoh, Serap
    Corvez, Maria
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 160 - 170
  • [32] Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Spicer, J.
    Baird, R.
    Suder, A.
    Cresti, N.
    Corbacho, J. Garcia
    Hogarth, L.
    Frenkel, E.
    Matsumoto, S.
    Kawabata, I.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (02) : 137 - 145
  • [33] Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
    Patricia LoRusso
    Karthik Venkatakrishnan
    E. Gabriela Chiorean
    Dennis Noe
    Jing-Tao Wu
    Serap Sankoh
    Maria Corvez
    Edward A. Sausville
    Investigational New Drugs, 2014, 32 : 160 - 170
  • [34] Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
    Decoster, L.
    Aftimos, P. G.
    Rottey, S.
    Prenen, H.
    Collignon, J. J.
    Mebis, J.
    Canon, J-L.
    Fastenaekels, V.
    Cappoen, N.
    Joris, S. R.
    De Greve, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S262 - S262
  • [35] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    Pullarkat, V
    Deo, Y
    Link, J
    Spears, L
    Marty, V
    Curnow, R
    Groshen, S
    Gee, C
    Weber, JS
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (01) : 9 - 21
  • [36] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    V. Pullarkat
    Y. Deo
    J. Link
    L. Spears
    V. Marty
    R. Curnow
    S. Groshen
    C. Gee
    J. S. Weber
    Cancer Immunology, Immunotherapy, 1999, 48 : 9 - 21
  • [37] Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)
    Hamilton, E.
    Vidula, N.
    Ma, C.
    LoRusso, P.
    Bagley, R. G.
    Yu, Z.
    Annett, M.
    Weitzman, A.
    Conlan, M. G.
    Weise, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
    Lu, J.
    Budd, G. T.
    Frentzas, S.
    Park, H.
    Shannon, C.
    Rugo, H. S.
    O'Shaughnessy, J.
    Demichele, A.
    Tolaney, S. M.
    Eek, R. W.
    McCartney, A.
    Cuff, K.
    Esserman, L.
    Alika, A.
    Xu, D.
    Li, M.
    Le, T.
    L'Heureux, D. Z.
    Yan, J.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S223 - S223
  • [39] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Tokuda, Y
    Watanabe, T
    Omuro, Y
    Ando, M
    Katsumata, N
    Okumura, A
    Ohta, M
    Fujii, H
    Sasaki, Y
    Niwa, T
    Tajima, T
    BRITISH JOURNAL OF CANCER, 1999, 81 (08) : 1419 - 1425
  • [40] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Y Tokuda
    T Watanabe
    Y Omuro
    M Ando
    N Katsumata
    A Okumura
    M Ohta
    H Fujii
    Y Sasaki
    T Niwa
    T Tajima
    British Journal of Cancer, 1999, 81 : 1419 - 1425
12345